Literature DB >> 25613768

Considerations for the development of shale gas in the United Kingdom.

Jake Hays1, Madelon L Finkel2, Michael Depledge3, Adam Law2, Seth B C Shonkoff4.   

Abstract

The United States shale gas boom has precipitated global interest in the development of unconventional oil and gas resources. Recently, government ministers in the United Kingdom started granting licenses that will enable companies to begin initial exploration for shale gas. Meanwhile, concern is increasing among the scientific community about the potential impacts of shale gas and other types of unconventional natural gas development (UGD) on human health and the environment. Although significant data gaps remain, there has been a surge in the number of articles appearing in the scientific literature, nearly three-quarters of which has been published since the beginning of 2013. Important lessons can be drawn from the UGD experience in the United States. Here we explore these considerations and argue that shale gas development policies in the UK and elsewhere should be informed by empirical evidence generated on environmental, public health, and social risks. Additionally, policy decisions should take into account the measured effectiveness of harm reduction strategies as opposed to hypothetical scenarios and purported best practices that lack empirical support.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Environmental health; Natural gas development; Policy; Shale gas; United Kingdom

Mesh:

Substances:

Year:  2015        PMID: 25613768     DOI: 10.1016/j.scitotenv.2015.01.004

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  1 in total

1.  Toward an Understanding of the Environmental and Public Health Impacts of Unconventional Natural Gas Development: A Categorical Assessment of the Peer-Reviewed Scientific Literature, 2009-2015.

Authors:  Jake Hays; Seth B C Shonkoff
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.